GTG Launches GeneType, A Novel Comprehensive Risk Assessment Test That Covers 100% Of Women At Risk Of Developing Breast And Ovarian Cancer
GTG Launches GeneType, A Novel Comprehensive Risk Assessment Test That Covers 100% Of Women At Risk Of Developing Breast And Ovarian Cancer
GTG推出GeneType，這是一項新的綜合風險評估測試，涵蓋了100％的有患乳腺癌和卵巢癌風險的女性
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease,
基因技術有限公司（澳大利亞證券交易所股票代碼：GTG，納斯達克股票代碼：GENE，“公司”，“GTG”）），基於基因組學的健康、保健和嚴重疾病測試領域的全球領導者，
is pleased to announce the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30, assesses a woman's risk of cancer due to hereditary, including those with common gene mutations, and sporadic disease.
很高興地宣佈，公司已經發布了其新的綜合風險評估測試，該測試涵蓋了100％的有患乳腺癌和卵巢癌風險的女性。這項創新測試適用於所有30歲以上的女性，旨在評估女性因遺傳而患癌症的風險，包括具有常見基因突變的女性以及散發性疾病。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間